Insight

Ajay Major: Liso-cel in DLBCL with secondary CNS diagnosis by Jennifer Crombie

Collage photo of Ajay Major and Jennifer Crombie

Nov 14, 2024, 12:33

Ajay Major: Liso-cel in DLBCL with secondary CNS diagnosis by Jennifer Crombie

Ajay Major, Assistant Professor of Medicine at the University of Colorado School of Medicine, shared a post on X about a new abstract by Jennifer Crombie, Hematologist/oncologist at Dana Farber’s Cancer Center:

“Liso-cel in DLBCL with secondary CNS diagnosis.

36 patients (CIBMTR), 83% parenchymal, 97% active diagnosis at CAR
ORR 64%, CR 53%, 1-yr DOR 55%
1-yr PFS 36%, OS 39%, almost all deaths from POD
G3 CRS 8%, ICANS 22% (no G4-5)

Still bad outcomes in this setting.”

“Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry”

Authors: Sairah Ahmed, Avyakta Kallam, Matthew Frigault, Marcelo Pasquini, Jennifer Crombie et al.

Ajay Major: Liso-cel in DLBCL with secondary CNS diagnosis by Jennifer Crombie

More posts featuring Ajay Major.

Ajay Major is an Assistant Professor of Medicine at the University of Colorado School of Medicine, specializing in lymphoma and CLL/SLL. He is the Founder and President of Pager Publications, as well as the Founder and Editor-in-Chief of in-House. Additionally, he serves as a Reviewer for the Bellevue Literary Review.

Ajay Major ASH24 Avyakta Kallam cancer CIBMTR Diffuse Large B-Cell Lymphoma DLBCL Jennifer Crombie Liso-cel Marcelo Pasquini Matthew Frigault OncoDaily Oncology Sairah Ahmed

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage